假设HIV治疗相关研究模式的可接受性:南非索韦托HIV感染者的横断面研究。

IF 1.5 4区 医学 Q4 IMMUNOLOGY
Fatima Laher, Mbalenhle Sibiya, Naledi Mahlangu, Kennedy Otwombe
{"title":"假设HIV治疗相关研究模式的可接受性:南非索韦托HIV感染者的横断面研究。","authors":"Fatima Laher, Mbalenhle Sibiya, Naledi Mahlangu, Kennedy Otwombe","doi":"10.1089/aid.2025.0002","DOIUrl":null,"url":null,"abstract":"<p><p>Various modalities are being explored in HIV cure-related research, but little is documented on their acceptability in Africa, where HIV is most prevalent. To address this, we conducted a cross-sectional study in Soweto, South Africa, assessing stated acceptability of five potential HIV cure-related research modalities and identifying associated factors. Between May and August 2024, we sampled 100 adults living with HIV who provided informed consent. Participants completed questionnaires of socio-demographics and the Theoretical Framework of Acceptability scale measuring general acceptability and seven constructs (affective attitude, burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs). We summarized data using descriptive statistics. We assessed factors associated with acceptability using univariate and multivariate logistic regression. We found that of 100 participants (44% female, median age 39 years), 66% were willing to accept an intervention that would allow lifelong remission (antiretroviral treatment-free control), 88% were willing if the intervention guaranteed remission for everyone treated, and 87% were willing if the intervention had minimal side effects. Total mean acceptability scores of hypothetical HIV cure-related research modalities were oral or injectable chemotherapeutics (3.8/5), intravenous or injectable antibodies (3.7/5), radiotherapy (3.3/5), transplantation (3.1/5), gene therapy (2.9/5), and across all modalities (3.4/5). Participants rated antibodies and chemotherapeutics with tied top scores for affective attitude (3.8/5) and self-efficacy (4.0/5); chemotherapeutics with top scores for perceived effectiveness (4.0/5), intervention coherence (4.1/5) and having least burden (3.2/5) and opportunity costs (3.3/5); and antibodies with the top score for ethicality (4.2/5). Acceptability was associated with non-binary gender and willingness to take an intervention achieving 2 years remission. In conclusion, people living with HIV have moderately high acceptability for oral or injectable chemotherapeutics and intravenous or injectable antibodies but would need more information about gene therapy, transplantation, and radiotherapy. Antibodies aligned highest with personal values, suggesting support for antibody research and applications.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acceptability of Hypothetical HIV Cure-Related Research Modalities: A Cross-Sectional Study of People Living with HIV in Soweto, South Africa.\",\"authors\":\"Fatima Laher, Mbalenhle Sibiya, Naledi Mahlangu, Kennedy Otwombe\",\"doi\":\"10.1089/aid.2025.0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Various modalities are being explored in HIV cure-related research, but little is documented on their acceptability in Africa, where HIV is most prevalent. To address this, we conducted a cross-sectional study in Soweto, South Africa, assessing stated acceptability of five potential HIV cure-related research modalities and identifying associated factors. Between May and August 2024, we sampled 100 adults living with HIV who provided informed consent. Participants completed questionnaires of socio-demographics and the Theoretical Framework of Acceptability scale measuring general acceptability and seven constructs (affective attitude, burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs). We summarized data using descriptive statistics. We assessed factors associated with acceptability using univariate and multivariate logistic regression. We found that of 100 participants (44% female, median age 39 years), 66% were willing to accept an intervention that would allow lifelong remission (antiretroviral treatment-free control), 88% were willing if the intervention guaranteed remission for everyone treated, and 87% were willing if the intervention had minimal side effects. Total mean acceptability scores of hypothetical HIV cure-related research modalities were oral or injectable chemotherapeutics (3.8/5), intravenous or injectable antibodies (3.7/5), radiotherapy (3.3/5), transplantation (3.1/5), gene therapy (2.9/5), and across all modalities (3.4/5). Participants rated antibodies and chemotherapeutics with tied top scores for affective attitude (3.8/5) and self-efficacy (4.0/5); chemotherapeutics with top scores for perceived effectiveness (4.0/5), intervention coherence (4.1/5) and having least burden (3.2/5) and opportunity costs (3.3/5); and antibodies with the top score for ethicality (4.2/5). Acceptability was associated with non-binary gender and willingness to take an intervention achieving 2 years remission. In conclusion, people living with HIV have moderately high acceptability for oral or injectable chemotherapeutics and intravenous or injectable antibodies but would need more information about gene therapy, transplantation, and radiotherapy. Antibodies aligned highest with personal values, suggesting support for antibody research and applications.</p>\",\"PeriodicalId\":7544,\"journal\":{\"name\":\"AIDS research and human retroviruses\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS research and human retroviruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/aid.2025.0002\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/aid.2025.0002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在艾滋病毒治疗相关研究中正在探索各种模式,但是关于这些模式在艾滋病毒最流行的非洲的可接受性的记录很少。为了解决这个问题,我们在南非索韦托进行了一项横断面研究,评估了五种潜在的艾滋病治疗相关研究模式的可接受性,并确定了相关因素。在2024年5月至8月期间,我们抽样了100名提供知情同意的成年艾滋病毒感染者。被试完成社会人口学问卷和可接受度理论框架量表,测量一般可接受度和七个构念(情感态度、负担、伦理、感知有效性、干预一致性、自我效能感、机会成本)。我们用描述性统计对数据进行汇总。我们使用单变量和多变量逻辑回归评估与可接受性相关的因素。我们发现,在100名参与者中(44%为女性,中位年龄39岁),66%的人愿意接受允许终身缓解的干预(无抗逆转录病毒治疗的控制),88%的人愿意接受干预,如果干预保证每个接受治疗的人都能缓解,87%的人愿意接受干预,如果干预的副作用最小。假设的HIV治疗相关研究方式的总平均可接受性评分为口服或注射化疗药物(3.8/5)、静脉注射或注射抗体(3.7/5)、放疗(3.3/5)、移植(3.1/5)、基因治疗(2.9/5)和所有方式(3.4/5)。参与者在情感态度(3.8/5)和自我效能(4.0/5)方面给抗体和化疗药物打分。在感知有效性(4.0/5)、干预一致性(4.1/5)得分最高、负担(3.2/5)和机会成本(3.3/5)得分最低的化疗药物;伦理性得分最高的抗体(4.2/5)。可接受性与非二元性别和接受干预达到2年缓解的意愿相关。总之,艾滋病毒感染者对口服或注射化疗药物以及静脉注射或注射抗体的可接受性中等,但需要更多关于基因治疗、移植和放疗的信息。抗体与个人价值观最一致,表明对抗体研究和应用的支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Acceptability of Hypothetical HIV Cure-Related Research Modalities: A Cross-Sectional Study of People Living with HIV in Soweto, South Africa.

Various modalities are being explored in HIV cure-related research, but little is documented on their acceptability in Africa, where HIV is most prevalent. To address this, we conducted a cross-sectional study in Soweto, South Africa, assessing stated acceptability of five potential HIV cure-related research modalities and identifying associated factors. Between May and August 2024, we sampled 100 adults living with HIV who provided informed consent. Participants completed questionnaires of socio-demographics and the Theoretical Framework of Acceptability scale measuring general acceptability and seven constructs (affective attitude, burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs). We summarized data using descriptive statistics. We assessed factors associated with acceptability using univariate and multivariate logistic regression. We found that of 100 participants (44% female, median age 39 years), 66% were willing to accept an intervention that would allow lifelong remission (antiretroviral treatment-free control), 88% were willing if the intervention guaranteed remission for everyone treated, and 87% were willing if the intervention had minimal side effects. Total mean acceptability scores of hypothetical HIV cure-related research modalities were oral or injectable chemotherapeutics (3.8/5), intravenous or injectable antibodies (3.7/5), radiotherapy (3.3/5), transplantation (3.1/5), gene therapy (2.9/5), and across all modalities (3.4/5). Participants rated antibodies and chemotherapeutics with tied top scores for affective attitude (3.8/5) and self-efficacy (4.0/5); chemotherapeutics with top scores for perceived effectiveness (4.0/5), intervention coherence (4.1/5) and having least burden (3.2/5) and opportunity costs (3.3/5); and antibodies with the top score for ethicality (4.2/5). Acceptability was associated with non-binary gender and willingness to take an intervention achieving 2 years remission. In conclusion, people living with HIV have moderately high acceptability for oral or injectable chemotherapeutics and intravenous or injectable antibodies but would need more information about gene therapy, transplantation, and radiotherapy. Antibodies aligned highest with personal values, suggesting support for antibody research and applications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
6.70%
发文量
201
审稿时长
3-6 weeks
期刊介绍: AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信